Patents by Inventor Olga Khorkova

Olga Khorkova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
    Patent number: 10036014
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: July 31, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF REPROGRAMMING FACTOR RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A REPROGRAMMING FACTOR
    Publication number: 20180208929
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 26, 2018
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE
    Publication number: 20180208930
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • TREATMENT OF ADIPONECTIN (ADIPOQ) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN ADIPONECTIN (ADIPOQ)
    Publication number: 20180201931
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Adiponectins (ADIPOQ)s.
    Type: Application
    Filed: March 6, 2018
    Publication date: July 19, 2018
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • Antagonat compositions and methods of use
    Patent number: 10000752
    Abstract: Provided herein are compositions, compounds, and methods of modulating gene expression. In certain embodiments described herein is a composition, wherein the composition comprises an antagoNAT. In some embodiments, the antagoNAT is an oligonucleotide comprising modified and unmodified sugar subunits, wherein the antagoNAT hybridizes with a natural antisense transcript. Certain embodiments of the present invention provide a method for modulating gene expression in a cell comprising contacting the cell with an antagoNAT. In some embodiments, the method includes forming a hybrid comprising the antagoNAT and a natural antisense transcript of the gene, wherein the hybrid sterically blocks the normal function of the natural antisense transcript.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: June 19, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon
  • TREATMENT OF ALPHA-L-IDURONIDASE (IDUA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IDUA
    Publication number: 20180135050
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.
    Type: Application
    Filed: December 19, 2017
    Publication date: May 17, 2018
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN, Carlos COITO, Gang SHEN
  • Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
    Patent number: 9970008
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Atonal homolog 1 (ATOH1), in particular, by targeting natural antisense polynucleotides of Atonal homolog 1 (ATOH1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of ATOH1.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: May 15, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT
    Patent number: 9957503
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotide of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: May 1, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
    Patent number: 9920322
    Abstract: Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 20, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3
    Patent number: 9920369
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Colony-stimulating factor 3 (CSF3), in particular, by targeting natural antisense polynucleotides of Colony-stimulating factor 3 (CSF3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CSF3.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: March 20, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
    Patent number: 9914923
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.
    Type: Grant
    Filed: January 1, 2015
    Date of Patent: March 13, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF INTERFERON REGULATORY FACTOR 8 (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRF8
    Publication number: 20180066260
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense polynucleotides of Interferon Regulatory Factor 8 (IRF8). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRF8.
    Type: Application
    Filed: October 31, 2017
    Publication date: March 8, 2018
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN
  • Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
    Patent number: 9909126
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Adiponectins (ADIPOQ)s.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 6, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1
    Patent number: 9902995
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Pyrroline-5-carboxylate reductase 1 (PYCR1), in particular, by targeting natural antisense polynucleotides of Pyrroline-5-carboxylate reductase 1 (PYCR1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PYCR1.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: February 27, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
    Patent number: 9902959
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Frataxin (FXN), in particular, by targeting natural antisense polynucleotides of Frataxin (FXN). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FXN.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: February 27, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
    Patent number: 9902958
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: February 27, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • TREATMENT OF DELTA-LIKE 1 HOMOLOG (DLK1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DLK1
    Publication number: 20180051286
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like 1 homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like 1 homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLK1.
    Type: Application
    Filed: November 6, 2017
    Publication date: February 22, 2018
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN, Carlos COITO
  • TREATMENT OF NANOG RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO NANOG
    Publication number: 20180037891
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of NANOG, in particular, by targeting natural antisense polynucleotides of NANOG. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NANOG.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 8, 2018
    Inventors: Joseph COLLARD, Olga KHORKOVA SHERMAN
  • Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
    Patent number: 9879256
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hepatocyte Growth Factor (HGF), in particular, by targeting natural antisense polynucleotides of Hepatocyte Growth Factor (HGF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HGF.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: January 30, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
    Patent number: 9879264
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: January 30, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman